Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy

Zeruesenay Desta, Roseann S. Gammal, Li Gong, Michelle Whirl-Carrillo, Aditya H. Gaur, Chonlaphat Sukasem, Jennifer Hockings, Alan Myers, Marelize Swart, Rachel F. Tyndale, Collen Masimirembwa, Otito F. Iwuchukwu, Sanika Chirwa, Jeffrey Lennox, Andrea Gaedigk, Teri E. Klein, David W. Haas

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
DOIs
StatePublished - Jan 1 2019

Fingerprint

efavirenz
Pharmacogenetics
Guidelines
Reverse Transcriptase Inhibitors
HIV Infections
HIV-1
Therapeutics
Central Nervous System
Genotype
Cytochrome P-450 CYP2B6

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. / Desta, Zeruesenay; Gammal, Roseann S.; Gong, Li; Whirl-Carrillo, Michelle; Gaur, Aditya H.; Sukasem, Chonlaphat; Hockings, Jennifer; Myers, Alan; Swart, Marelize; Tyndale, Rachel F.; Masimirembwa, Collen; Iwuchukwu, Otito F.; Chirwa, Sanika; Lennox, Jeffrey; Gaedigk, Andrea; Klein, Teri E.; Haas, David W.

In: Clinical Pharmacology and Therapeutics, 01.01.2019.

Research output: Contribution to journalArticle

Desta, Z, Gammal, RS, Gong, L, Whirl-Carrillo, M, Gaur, AH, Sukasem, C, Hockings, J, Myers, A, Swart, M, Tyndale, RF, Masimirembwa, C, Iwuchukwu, OF, Chirwa, S, Lennox, J, Gaedigk, A, Klein, TE & Haas, DW 2019, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy', Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.1477
Desta, Zeruesenay ; Gammal, Roseann S. ; Gong, Li ; Whirl-Carrillo, Michelle ; Gaur, Aditya H. ; Sukasem, Chonlaphat ; Hockings, Jennifer ; Myers, Alan ; Swart, Marelize ; Tyndale, Rachel F. ; Masimirembwa, Collen ; Iwuchukwu, Otito F. ; Chirwa, Sanika ; Lennox, Jeffrey ; Gaedigk, Andrea ; Klein, Teri E. ; Haas, David W. / Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. In: Clinical Pharmacology and Therapeutics. 2019.
@article{0f60f906483542b99ee7dffe3d85b2bd,
title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy",
abstract = "The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.",
author = "Zeruesenay Desta and Gammal, {Roseann S.} and Li Gong and Michelle Whirl-Carrillo and Gaur, {Aditya H.} and Chonlaphat Sukasem and Jennifer Hockings and Alan Myers and Marelize Swart and Tyndale, {Rachel F.} and Collen Masimirembwa and Iwuchukwu, {Otito F.} and Sanika Chirwa and Jeffrey Lennox and Andrea Gaedigk and Klein, {Teri E.} and Haas, {David W.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/cpt.1477",
language = "English (US)",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy

AU - Desta, Zeruesenay

AU - Gammal, Roseann S.

AU - Gong, Li

AU - Whirl-Carrillo, Michelle

AU - Gaur, Aditya H.

AU - Sukasem, Chonlaphat

AU - Hockings, Jennifer

AU - Myers, Alan

AU - Swart, Marelize

AU - Tyndale, Rachel F.

AU - Masimirembwa, Collen

AU - Iwuchukwu, Otito F.

AU - Chirwa, Sanika

AU - Lennox, Jeffrey

AU - Gaedigk, Andrea

AU - Klein, Teri E.

AU - Haas, David W.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.

AB - The HIV type-1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type-1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic variants may be at increased risk for adverse effects, particularly central nervous system toxicity and treatment discontinuation. We summarize the evidence from the literature and provide therapeutic recommendations for efavirenz prescribing based on CYP2B6 genotypes.

UR - http://www.scopus.com/inward/record.url?scp=85068533591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068533591&partnerID=8YFLogxK

U2 - 10.1002/cpt.1477

DO - 10.1002/cpt.1477

M3 - Article

C2 - 31006110

AN - SCOPUS:85068533591

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -